Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 20 12 2022
accepted: 11 04 2024
medline: 29 5 2024
pubmed: 29 5 2024
entrez: 28 5 2024
Statut: aheadofprint

Résumé

Epstein-Barr virus (EBV) is an aetiologic risk factor for the development of multiple sclerosis (MS). However, the role of EBV-infected B cells in the immunopathology of MS is not well understood. Here we characterized spontaneous lymphoblastoid cell lines (SLCLs) isolated from MS patients and healthy controls (HC) ex vivo to study EBV and host gene expression in the context of an individual's endogenous EBV. SLCLs derived from MS patient B cells during active disease had higher EBV lytic gene expression than SLCLs from MS patients with stable disease or HCs. Host gene expression analysis revealed activation of pathways associated with hypercytokinemia and interferon signalling in MS SLCLs and upregulation of forkhead box protein 1 (FOXP1), which contributes to EBV lytic gene expression. We demonstrate that antiviral approaches targeting EBV replication decreased cytokine production and autologous CD4

Identifiants

pubmed: 38806670
doi: 10.1038/s41564-024-01699-6
pii: 10.1038/s41564-024-01699-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : RO1 CA093606
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
ID : RO1 DE017336
Organisme : NIAID NIH HHS
ID : R01 AI153508
Pays : United States

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Young, L. S., Yap, L. F. & Murray, P. G. Epstein–Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789–802 (2016).
pubmed: 27687982 doi: 10.1038/nrc.2016.92
Thorley-Lawson, D. A. EBV persistence–introducing the virus. Curr. Top. Microbiol. Immunol. 390, 151–209 (2015).
pubmed: 26424647 pmcid: 5125397
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. & Hislop, A. D. The immunology of Epstein–Barr virus-induced disease. Annu. Rev. Immunol. 33, 787–821 (2015).
pubmed: 25706097 doi: 10.1146/annurev-immunol-032414-112326
Soldan, S. S. & Lieberman, P. M. Epstein–Barr virus infection in the development of neurological disorders. Drug Discov. Today Dis. Models 32, 35–52 (2020).
pubmed: 33897799 pmcid: 8059607 doi: 10.1016/j.ddmod.2020.01.001
Soldan, S. S. & Lieberman, P. M. Epstein–Barr virus and multiple sclerosis. Nat. Rev. Microbiol. 21, 51–64 (2023).
Dobson, R. & Giovannoni, G. Multiple sclerosis – a review. Eur. J. Neurol. 26, 27–40 (2019).
pubmed: 30300457 doi: 10.1111/ene.13819
Bray, P. F., Bloomer, L. C., Salmon, V. C., Bagley, M. H. & Larsen, P. D. Epstein–Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch. Neurol. 40, 406–408 (1983).
pubmed: 6860175 doi: 10.1001/archneur.1983.04050070036006
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science 375, 296–301 (2022).
pubmed: 35025605 doi: 10.1126/science.abj8222
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321–327 (2022).
pubmed: 35073561 pmcid: 9382663 doi: 10.1038/s41586-022-04432-7
Sundstrom, P., Nystrom, M., Ruuth, K. & Lundgren, E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 215, 102–107 (2009).
pubmed: 19733917 doi: 10.1016/j.jneuroim.2009.08.004
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis—from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399–414 (2021).
pubmed: 34075251 doi: 10.1038/s41582-021-00498-5
Enose-Akahata, Y. et al. Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases. PLoS Pathog. 14, e1007042 (2018).
pubmed: 29709026 pmcid: 5945224 doi: 10.1371/journal.ppat.1007042
Li, R. et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J. Immunol. 198, 691–698 (2017).
pubmed: 27974457 doi: 10.4049/jimmunol.1601649
Matsushita, T. et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE 8, e61835 (2013).
pubmed: 23637915 pmcid: 3630114 doi: 10.1371/journal.pone.0061835
Mandage, R. et al. Genetic factors affecting EBV copy number in lymphoblastoid cell lines derived from the 1000 Genome Project samples. PLoS ONE 12, e0179446 (2017).
pubmed: 28654678 pmcid: 5487016 doi: 10.1371/journal.pone.0179446
SoRelle, E. D. et al. Single-cell RNA-seq reveals transcriptomic heterogeneity mediated by host–pathogen dynamics in lymphoblastoid cell lines. Elife https://doi.org/10.7554/eLife.62586 (2021).
Sculley, T. B., Moss, D. J., Hazelton, R. A. & Pope, J. H. Detection of Epstein–Barr virus strain variants in lymphoblastoid cell lines ‘spontaneously’ derived from patients with rheumatoid arthritis, infectious mononucleosis and normal controls. J. Gen. Virol. 68, 2069–2078 (1987).
pubmed: 3039039 doi: 10.1099/0022-1317-68-8-2069
Lewin, N. et al. Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int. J. Cancer 39, 472–476 (1987).
pubmed: 3030940 doi: 10.1002/ijc.2910390411
Monaco, M. C. G. et al. EBNA1 inhibitors block proliferation of spontaneous lymphoblastoid cell lines from patients with multiple sclerosis and healthy controls. Neurol. Neuroimmunol. Neuroinflamm. https://doi.org/10.1212/NXI.0000000000200149 (2023).
Munch, M. et al. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein–Barr virus. Mult. Scler. 1, 78–81 (1995).
pubmed: 9345456 doi: 10.1177/135245859500100204
Christensen, T., Tonjes, R. R., zur Megede, J., Boller, K. & Moller-Larsen, A. Reverse transcriptase activity and particle production in B lymphoblastoid cell lines established from lymphocytes of patients with multiple sclerosis. AIDS Res. Hum. Retroviruses 15, 285–291 (1999).
pubmed: 10052759 doi: 10.1089/088922299311466
Gao, Y., Smith, P. R., Karran, L., Lu, Q. L. & Griffin, B. E. Induction of an exceptionally high-level, nontranslated, Epstein–Barr virus-encoded polyadenylated transcript in the Burkitt’s lymphoma line Daudi. J. Virol. 71, 84–94 (1997).
pubmed: 8985326 pmcid: 191027 doi: 10.1128/jvi.71.1.84-94.1997
Dheekollu, J. et al. Carcinoma-risk variant of EBNA1 deregulates Epstein–Barr Virus episomal latency. Oncotarget 8, 7248–7264 (2017).
pubmed: 28077791 pmcid: 5352318 doi: 10.18632/oncotarget.14540
Sivachandran, N., Wang, X. & Frappier, L. Functions of the Epstein–Barr virus EBNA1 protein in viral reactivation and lytic infection. J. Virol. 86, 6146–6158 (2012).
pubmed: 22491455 pmcid: 3372196 doi: 10.1128/JVI.00013-12
Mrozek-Gorska, P. et al. Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc. Natl Acad. Sci. USA 116, 16046–16055 (2019).
pubmed: 31341086 pmcid: 6690029 doi: 10.1073/pnas.1901314116
Fischer, E. M. et al. Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes. Int. Immunol. 11, 1841–1849 (1999).
pubmed: 10545488 doi: 10.1093/intimm/11.11.1841
Schneider-Schaulies, J., Dunster, L. M., Kobune, F., Rima, B. & ter Meulen, V. Differential downregulation of CD46 by measles virus strains. J. Virol. 69, 7257–7259 (1995).
pubmed: 7474148 pmcid: 189648 doi: 10.1128/jvi.69.11.7257-7259.1995
Santoro, F. et al. CD46 is a cellular receptor for human herpesvirus 6. Cell 99, 817–827 (1999).
pubmed: 10619434 doi: 10.1016/S0092-8674(00)81678-5
Sun, H. et al. Tim3
pubmed: 28478516 doi: 10.1007/s10753-017-0577-6
Miteva, L., Trenova, A., Slavov, G. & Stanilova, S. IL12B gene polymorphisms have sex-specific effects in relapsing-remitting multiple sclerosis. Acta Neurol. Belg. 119, 83–93 (2019).
pubmed: 30554348 doi: 10.1007/s13760-018-01066-3
Parnell, G. P. et al. The latitude-dependent autoimmune disease risk genes ZMIZ1 and IRF8 regulate mononuclear phagocytic cell differentiation in response to vitamin D. Hum. Mol. Genet. 28, 269–278 (2019).
pubmed: 30285234
McWilliam, O., Sellebjerg, F., Marquart, H. V. & von Essen, M. R. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response. J. Neuroimmunol. 324, 157–164 (2018).
pubmed: 30244922 doi: 10.1016/j.jneuroim.2018.09.001
Maltby, V. E. et al. Genome-wide DNA methylation changes in CD19
pubmed: 30479356 pmcid: 6258668 doi: 10.1038/s41598-018-35603-0
Thompson, M. P., Aggarwal, B. B., Shishodia, S., Estrov, Z. & Kurzrock, R. Autocrine lymphotoxin production in Epstein–Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia 17, 2196–2201 (2003).
pubmed: 14523478 doi: 10.1038/sj.leu.2403130
Drosu, N. C., Edelman, E. R. & Housman, D. E. Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc. Natl Acad. Sci. USA 117, 12368–12374 (2020).
pubmed: 32409608 pmcid: 7275665 doi: 10.1073/pnas.2002392117
SoRelle, E. D. et al. Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein–Barr virus infection. Cell Rep. 40, 111286 (2022).
pubmed: 36044865 pmcid: 9879279 doi: 10.1016/j.celrep.2022.111286
Pender, M. P., Csurhes, P. A., Burrows, J. M. & Burrows, S. R. Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis. Clin. Transl. Immunol. 6, e126 (2017).
doi: 10.1038/cti.2016.87
Angelini, D. F. et al. Increased CD8
pubmed: 23592979 pmcid: 3623710 doi: 10.1371/journal.ppat.1003220
Delecluse, S. et al. Identification and cloning of a new western Epstein–Barr virus strain that efficiently replicates in primary B cells. J. Virol. https://doi.org/10.1128/JVI.01918-19 (2020).
Weisel, N. M. et al. Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype. Blood 136, 2774–2785 (2020).
pubmed: 32750113 pmcid: 7731793 doi: 10.1182/blood.2019002782
SoRelle, E. D., Reinoso-Vizcaino, N. M., Horn, G. Q. & Luftig, M. A. Epstein–Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro. Front. Immunol. 13, 1001145 (2022).
pubmed: 36248899 pmcid: 9554744 doi: 10.3389/fimmu.2022.1001145
Yang, R. et al. Human T-bet governs the generation of a distinct subset of CD11c
pubmed: 35867801 pmcid: 9413977 doi: 10.1126/sciimmunol.abq3277
Mouat, I. C. et al. Gammaherpesvirus infection drives age-associated B cells toward pathogenicity in EAE and MS. Sci. Adv. 8, eade6844 (2022).
pubmed: 36427301 pmcid: 9699667 doi: 10.1126/sciadv.ade6844
Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C. & Aloisi, F. Transcriptional profile and Epstein–Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J. Neuroinflammation 15, 18 (2018).
pubmed: 29338732 pmcid: 5771146 doi: 10.1186/s12974-017-1049-5
Moreno, M. A. et al. Molecular signature of Epstein–Barr virus infection in MS brain lesions. Neurol. Neuroimmunol. Neuroinflamm. 5, e466 (2018).
pubmed: 29892607 pmcid: 5994704 doi: 10.1212/NXI.0000000000000466
Hong, T. et al. Epstein–Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci. Genome Res. 31, 2185–2198 (2021).
pubmed: 34799401 pmcid: 8647835 doi: 10.1101/gr.264705.120
Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699–707 (2018).
pubmed: 29662164 pmcid: 6022759 doi: 10.1038/s41588-018-0102-3
Ramasamy, R., Mohammed, F. & Meier, U. C. HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein–Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis. Immunol. Lett. 217, 15–24 (2020).
pubmed: 31689443 doi: 10.1016/j.imlet.2019.10.017
Mansouri, S., Pan, Q., Blencowe, B. J., Claycomb, J. M. & Frappier, L. Epstein–Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J. Virol. 88, 11166–11177 (2014).
pubmed: 25031339 pmcid: 4178782 doi: 10.1128/JVI.01785-14
Sagardoy, A. et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood 121, 4311–4320 (2013).
pubmed: 23580662 pmcid: 3713421 doi: 10.1182/blood-2012-10-462846
Patzelt, T. et al. Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells. Proc. Natl Acad. Sci. USA 115, 3120–3125 (2018).
pubmed: 29507226 pmcid: 5866538 doi: 10.1073/pnas.1711335115
Wang, J. et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat. Commun. 13, 866 (2022).
pubmed: 35165282 pmcid: 8844414 doi: 10.1038/s41467-022-28479-2
Torkildsen, Ø., Myhr, K. M., Skogen, V., Steffensen, L. H. & Bjørnevik, K. Tenofovir as a treatment option for multiple sclerosis. Mult. Scler. Relat. Disord. 46, 102569 (2020).
pubmed: 33049462 doi: 10.1016/j.msard.2020.102569
Latifi, T., Zebardast, A. & Marashi, S. M. The role of human endogenous retroviruses (HERVs) in multiple sclerosis and the plausible interplay between HERVs, Epstein–Barr virus infection, and vitamin D. Mult. Scler. Relat. Disord. 57, 103318 (2022).
pubmed: 35158423 doi: 10.1016/j.msard.2021.103318
Kubuschok, B. et al. Gene-modified spontaneous Epstein–Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model. Cancer Gene Ther. 7, 1231–1240 (2000).
pubmed: 11023195 doi: 10.1038/sj.cgt.7700236
Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
pubmed: 22035192 pmcid: 3216358 doi: 10.1021/ac202028g
Lin, C. T., Leibovitch, E. C., Almira-Suarez, M. I. & Jacobson, S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect. Agent Cancer 11, 32 (2016).
pubmed: 27462365 pmcid: 4960850 doi: 10.1186/s13027-016-0081-x
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
Čejková, D., Strouhal, M., Norris, S. J., Weinstock, G. M. & Šmajs, D. A retrospective study on genetic heterogeneity within Treponema strains: subpopulations are genetically distinct in a limited number of positions. PLoS Negl. Trop. Dis. 9, e0004110 (2015).
pubmed: 26436423 pmcid: 4593590 doi: 10.1371/journal.pntd.0004110
Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience https://doi.org/10.1093/gigascience/giab008 (2021).
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
pubmed: 23329690 pmcid: 3603318 doi: 10.1093/molbev/mst010
Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307–321 (2010).
pubmed: 20525638 doi: 10.1093/sysbio/syq010
Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 49, W293–W296 (2021).
pubmed: 33885785 pmcid: 8265157 doi: 10.1093/nar/gkab301
Felsenstein, J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39, 783–791 (1985).
pubmed: 28561359 doi: 10.2307/2408678
Zanella, L. et al. A reliable Epstein–Barr Virus classification based on phylogenomic and population analyses. Sci. Rep. 9, 9829 (2019).
pubmed: 31285478 pmcid: 6614506 doi: 10.1038/s41598-019-45986-3
Argimon, S. et al. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. Microb. Genom. 2, e000093 (2016).
pubmed: 28348833 pmcid: 5320705
Messick, T. E. et al. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein–Barr virus latent infection and tumor growth. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aau5612 (2019).
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
pubmed: 19261174 pmcid: 2690996 doi: 10.1186/gb-2009-10-3-r25
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
pubmed: 21816040 pmcid: 3163565 doi: 10.1186/1471-2105-12-323
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Zhao, T. & Wang, Z. GraphBio: a shiny web app to easily perform popular visualization analysis for omics data. Front. Genet. 13, 957317 (2022).
pubmed: 36159985 pmcid: 9490469 doi: 10.3389/fgene.2022.957317
Afrasiabi, A. et al. Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus. J. Autoimmun. 127, 102781 (2022).
pubmed: 34952359 doi: 10.1016/j.jaut.2021.102781

Auteurs

Samantha S Soldan (SS)

The Wistar Institute, Philadelphia, PA, USA.

Chenhe Su (C)

The Wistar Institute, Philadelphia, PA, USA.

Maria Chiara Monaco (MC)

Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.

Leena Yoon (L)

The Wistar Institute, Philadelphia, PA, USA.

Toshitha Kannan (T)

The Wistar Institute, Philadelphia, PA, USA.

Urvi Zankharia (U)

The Wistar Institute, Philadelphia, PA, USA.

Rishi J Patel (RJ)

The Wistar Institute, Philadelphia, PA, USA.

Jayaraju Dheekollu (J)

The Wistar Institute, Philadelphia, PA, USA.

Olga Vladimirova (O)

The Wistar Institute, Philadelphia, PA, USA.

Jack W Dowling (JW)

The Wistar Institute, Philadelphia, PA, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Simon Thebault (S)

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Natalie Brown (N)

The Wistar Institute, Philadelphia, PA, USA.

Annaliese Clauze (A)

Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.

Frances Andrada (F)

Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.

Andries Feder (A)

Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Paul J Planet (PJ)

Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Andrew Kossenkov (A)

The Wistar Institute, Philadelphia, PA, USA.

Daniel E Schäffer (DE)

The Wistar Institute, Philadelphia, PA, USA.

Joan Ohayon (J)

Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.

Noam Auslander (N)

The Wistar Institute, Philadelphia, PA, USA.

Steven Jacobson (S)

Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.

Paul M Lieberman (PM)

The Wistar Institute, Philadelphia, PA, USA. lieberman@wistar.org.

Classifications MeSH